MXPA06003748A - Fused lactam compounds. - Google Patents

Fused lactam compounds.

Info

Publication number
MXPA06003748A
MXPA06003748A MXPA06003748A MXPA06003748A MXPA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A
Authority
MX
Mexico
Prior art keywords
group
disease
compound
substituents
pharmaceutically
Prior art date
Application number
MXPA06003748A
Other languages
Spanish (es)
Inventor
Masako Hirota
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA06003748A publication Critical patent/MXPA06003748A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or substituted and said ary is substituted by at least one substituer,t selected from the group consisting of substituents a; said substituents a are selected from the group 10 consisting of halogen ate ms, alkyl groups having from 1 to 6 carbon atoms etc.; or a pharmaceutically ac eptable ester of such compound, or a pharmaceutically ac eptable salt thereof. These compou ds are useful for the treatment of disease conditions caused 15 by overactivation of N DA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composi ion comprising the above compound.
MXPA06003748A 2003-10-08 2004-09-27 Fused lactam compounds. MXPA06003748A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50967003P 2003-10-08 2003-10-08
PCT/IB2004/003125 WO2005035523A1 (en) 2003-10-08 2004-09-27 Fused lactam compounds

Publications (1)

Publication Number Publication Date
MXPA06003748A true MXPA06003748A (en) 2006-06-14

Family

ID=34435007

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06003748A MXPA06003748A (en) 2003-10-08 2004-09-27 Fused lactam compounds.

Country Status (6)

Country Link
EP (1) EP1673367A1 (en)
JP (1) JP2007508288A (en)
BR (1) BRPI0415113A (en)
CA (1) CA2541162A1 (en)
MX (1) MXPA06003748A (en)
WO (1) WO2005035523A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097782A1 (en) * 2004-04-07 2005-10-20 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivative
CN103002893B (en) 2010-07-30 2017-05-10 东丽株式会社 Therapeutic agent or prophylactic agent for neuropathic pain
EP2838530B1 (en) 2012-04-20 2017-04-05 UCB Biopharma SPRL Methods for treating parkinson's disease
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA3001894A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE192149T1 (en) * 1990-05-10 2000-05-15 Pfizer NEUROPROTECTIVE INDOLONES AND RELATED DERIVATIVES
RU2065859C1 (en) * 1991-07-17 1996-08-27 Пфайзер Инк. 2-(4-hydroxypiperidino)-1-alkanol derivatives and 2-(4- hydroxypiperidino)-1-alkanone derivatives
FR2688504B1 (en) * 1992-03-13 1995-05-05 Synthelabo DERIVATIVES OF 2- (PIPERIDIN-1-YL) ETHANOL, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
KR950704298A (en) * 1992-10-30 1995-11-17 알렌 제이.스피겔 Neuroprotective 3,4-dihydro-2 (1H) -quinolone compounds (NEUROPROTECTIVE 3,4-DIHYDRO-2 (1H) -QUINOLONE COMPOUNDS)
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

Also Published As

Publication number Publication date
WO2005035523A1 (en) 2005-04-21
EP1673367A1 (en) 2006-06-28
CA2541162A1 (en) 2005-04-21
BRPI0415113A (en) 2006-11-28
JP2007508288A (en) 2007-04-05

Similar Documents

Publication Publication Date Title
RS20060143A (en) Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
MXPA05010824A (en) Bicyclic compounds as nr2b receptor antagonists.
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
HUP0303756A2 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them
MXPA02011417A (en) Substituted 1 aminoalkyl lactams and their use as muscarinic receptor antagonists.
TW200716528A (en) Cyclopropanecarboxamide derivatives
MY142807A (en) Benzimidazole derivative and use thereof.
CA2383779A1 (en) N-(indolecarbonyl)piperazine derivatives
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
MXPA06003748A (en) Fused lactam compounds.
MXPA02011418A (en) Substituted 1 aminoalkyl lactams and their use as muscarinic receptor antagonists.
KR970705542A (en) Neuroprotective 3- (piperidinyl-1) -chroman-4,7-diol and 1- (4-hydrophenyl) -2- (piperidinyl-1) -alkanol derivative (NEUROPROTECTIVE 3- -1) -CHROMAN-4,7-DIOL AND 1- (4-HYDROPHENYL) -2- (PIPERIDINYL-1) -ALCANOL DERIVATIVES
HUP0500201A2 (en) Polycyclic compounds as potent alpha2-adrenoceptor antagonists and pharmaceutical compositions thereof
BR0016951A (en) Phenylpiperazinyl derivative, compound, pharmaceutical composition, use thereof, method of treatment
NZ515407A (en) 4-Phenyl-pyrimidine derivatives
BRPI0415109A (en) 1- [2- (4-hydroxyphenyl) -2-hydroxyethyl] -piperidin-4-ol compounds as nmda receptor antagonists
MXPA02011464A (en) 1,4 diazepan 2,5 dione derivatives and their use as nk 1 receptor antagonists.
CO5180624A1 (en) MUSCARINIC ANTAGONISTS
CA2450274A1 (en) Benzoxazepine derivatives and their use as ampa receptor stimulators
DE60000978T2 (en) 22R-HYDROXYCHOLESTA-8,14-DIENE DERIVATIVES FOR INHIBITING MEIOSE
HUP0201863A2 (en) Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing the same
KR880005138A (en) New compounds
JP2016000700A (en) 2-amino substituted pyridine derivative